Allergy Causes and Triggers: What Sets Off an Immune Response

Allergies affect an estimated 50 million people in the United States each year, according to the American College of Allergy, Asthma & Immunology (ACAAI), making the mechanisms behind immune overreaction one of the most clinically significant topics in everyday medicine. This page covers what allergens are, how they activate the immune system, which substances and environments most commonly trigger reactions, and how clinicians distinguish true allergic responses from other forms of sensitivity. Understanding these boundaries shapes diagnosis, treatment selection, and risk management across allergy practice in the United States.

Definition and Scope

An allergen is any ordinarily harmless substance that the immune system of a sensitized individual misidentifies as a threat. The immune system mounts a defense — producing Immunoglobulin E (IgE) antibodies, releasing histamine, and initiating inflammatory cascades — in response to proteins that pose no biological danger to non-sensitized people.

The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, classifies allergic diseases as a major public health concern. NIAID research has established that the genetic predisposition to produce IgE antibodies against environmental proteins — called atopy — underlies the majority of clinical allergy diagnoses, though atopy alone does not guarantee that symptoms will develop.

The scope of allergens recognized in clinical practice spans at least six major substance classes:

  1. Aeroallergens — airborne particles such as pollen, mold spores, dust mite fecal proteins, and pet dander
  2. Food proteins — most commonly peanut, tree nut, milk, egg, wheat, soy, fish, and shellfish (the "Big 9" defined under the FASTER Act of 2021)
  3. Insect venoms — proteins in the stings of Hymenoptera species (bees, wasps, hornets, fire ants)
  4. Drug compounds — penicillin and related beta-lactam antibiotics account for the largest share of reported drug allergy diagnoses
  5. Latex — proteins in natural rubber derived from Hevea brasiliensis
  6. Contact allergens — nickel, fragrances, preservatives, and plant resins such as urushiol from poison ivy

For a broader classification framework, types of allergies organizes these categories by organ system and clinical presentation.

How It Works

Allergic sensitization occurs in two distinct phases before any symptomatic reaction takes place.

Phase 1 — Sensitization: On first exposure to an allergen, antigen-presenting cells in the mucosa process the foreign protein and present it to T-helper 2 (Th2) lymphocytes. This Th2-skewed response drives B cells to produce IgE antibodies specific to that allergen. Those IgE molecules bind to high-affinity receptors (FcεRI) on mast cells and basophils throughout the body's tissues. No symptoms occur during sensitization.

Phase 2 — Elicitation: On subsequent exposure, the allergen cross-links the IgE molecules already sitting on mast cells and basophils. This cross-linking triggers degranulation — the rapid release of preformed mediators including histamine, tryptase, and heparin — along with the synthesis of prostaglandins and leukotrienes. Histamine binding to H1 receptors produces the classic triad: vasodilation, increased vascular permeability, and stimulation of sensory nerves (producing itch and sneezing). Leukotrienes drive prolonged bronchoconstriction, which is central to allergic asthma.

The World Allergy Organization (WAO) classifies this IgE-mediated pathway as a Type I hypersensitivity reaction under the Gell and Coombs classification system. Non-IgE-mediated reactions — including certain drug reactions and some food sensitivities — proceed through T-cell pathways (Type IV) without mast cell degranulation, a distinction that has direct consequences for diagnostic testing and treatment.

Common Scenarios

The clinical picture of allergy varies substantially depending on the route of exposure and the tissue where mast cells degranulate.

Inhalation (respiratory tract): Pollen from grasses, trees, and weeds accounts for the dominant trigger load in seasonal allergies. Grass pollen alone triggers symptoms in roughly 40% of allergy sufferers in the US, according to ACAAI data. Indoor aeroallergens — including dust mite proteins (Der p 1 and Der f 1) and cat albumin (Fel d 1) — drive perennial allergic rhinitis and are implicated in up to 80% of asthma cases in children, per NIAID published research.

Ingestion (gastrointestinal and systemic): Food allergies produce reactions ranging from oral tingling (as seen in oral allergy syndrome) to systemic anaphylaxis. Peanut allergy affects approximately 2.5% of children in the United States (NIAID Guidelines for the Diagnosis and Management of Food Allergy, 2010). The threshold dose that triggers a reaction differs between individuals — a fact that complicates food labeling policy governed by the Food Allergy Labeling and Consumer Protection Act (FALCPA) and its successor provisions.

Injection or sting: Insect sting allergies are the leading cause of anaphylaxis treated in US emergency departments, with an estimated 90 to 100 deaths attributed to sting-related anaphylaxis annually, per ACAAI mortality data.

Skin contact: Nickel — present in jewelry, belt buckles, and electronic devices — is the most prevalent contact allergen identified in North America. Skin allergies and contact dermatitis represent a distinct immunologic pathway (Type IV delayed hypersensitivity) that does not involve IgE.

The regulatory context for allergy in the United States addresses how federal agencies including the FDA, USDA, and NIAID frame allergen labeling, clinical trial standards, and workplace exposure rules for occupationally sensitized workers.

Decision Boundaries

Not every adverse reaction to a substance is an allergy. The clinical and regulatory distinction between allergy and other forms of sensitivity is consequential for both patient management and diagnostic coding.

Allergic reaction vs. food intolerance: A true food allergy involves an immune-mediated IgE response. Lactose intolerance involves enzymatic deficiency (absence of sufficient lactase), produces gastrointestinal symptoms but no IgE antibodies, and carries no risk of anaphylaxis. The allergy vs. intolerance distinction is formally addressed in NIAID diagnostic guidelines.

Allergic reaction vs. pharmacologic reaction: Aspirin and NSAIDs can trigger urticaria and bronchospasm through cyclooxygenase (COX-1) inhibition — a pharmacologic mechanism, not IgE-mediated allergy. These reactions are clinically significant but do not produce allergen-specific IgE and will not test positive on standard skin prick or serum IgE assays.

Allergic sensitization vs. clinical allergy: A positive IgE test to a specific allergen indicates sensitization — the presence of allergen-specific IgE antibodies — but does not by itself confirm clinical allergy. NIAID guidelines note that sensitization rates in population studies consistently exceed rates of reported clinical symptoms, meaning a positive test requires clinical correlation before a diagnosis is made.

Atopic vs. non-atopic disease: Atopic individuals — those with a genetic tendency toward IgE overproduction — are at elevated risk for the sequential progression of conditions described in allergy and the atopic march: eczema in infancy, followed by food allergy, then allergic rhinitis, and finally asthma. Non-atopic individuals can still develop isolated contact dermatitis or drug hypersensitivity through T-cell mechanisms without fitting the atopic profile.

Establishing these boundaries is a prerequisite for selecting the correct diagnostic pathway, whether that involves skin prick testing, allergy blood tests, or oral food challenge.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)